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Abstract
Introduction: Patients undergoing coronary revascularization often require inotropic support that has been
associated with an increased risk for death and morbidity. The purpose of this study was to evaluate the effect of
levosimendan versus control on survival after coronary revascularization.
Methods: A systemic review and meta-analysis of the literature was carried out on published randomized
controlled clinical trials that investigated the efficacy of levosimendan compared to other therapy in patients
having coronary revascularisaion. The databases searched were Pubmed, EMBASE, the Cochrane Registry of Clinical
Trials and the metaRegister of Controlled Trials. Studies that compared levosimendan to any other therapy for
coronary revascularisation in adult humans and reported at least one outcome of interest were considered for
inclusion. Both percutaneous coronary intervention and cardiac surgery were included. Data extraction was
performed independently by two reviewers using predefined criteria. Relevant outcomes included mortality, cardiac
index, cardiac enzymes, length of stay and post-procedural atrial fibrillation.
Results: The meta-analysis included 729 patients from 17 studies. Levosimendan was associated with a mortality
reduction after coronary revascularization, (19/386 in the levosimendan group vs 39/343 in the control arm) odds
ratio (OR) 0.40 (95% confidence interval (CI) 0.21 to 0.76, P for overall effect 0.005, P for heterogeneity = 0.33, I2 =
12% with a total of 729 patients. Levosimendan also had a favourable effect on cardiac index (standardised mean
difference 1.63, 95% CI 1.43 to 1.83, P for overall effect < 0.00001), length of intensive care stay (random effects
model, mean difference - 26.18 hours 95% CI 46.20 to 6.16, P for heterogeneity < 0.00001, I2 = 95%, P for overall
effect P = 0.01), reductions in the rate of atrial fibrillation (OR 0.54, 95% CI 0.36 to 0.82, P for effect = 0.004, P for
heterogeneity 0.84, I2 = 0% for 465 patients) and troponin I levels group (mean difference -1.59, 95% CI 1.78 to
1.40, P for overall effect < 0.00001, P for heterogeneity < 0.00001, I2 = 95%). Limitations of this analysis are
discussed.
Conclusions: Levosimendan is associated with a significant improvement in mortality after coronary
revascularization. There are also improvements in several secondary endpoints. A suitably powered randomised
controlled trial is required to confirm these findings and to address the unresolved questions about the timing and
dosing of levosimendan.
Introduction
Following coronary revascularisation, patients are still
vulnerable to a low cardiac output state and tissue hypo-
perfusion. Some patients may require bridging therapy
in order to realise the benefits of revascularisation.
There is substantial geographic variation, but it is
estimated that between 8 and 25% of patients under-
going coronary revascularisation require inotropic sup-
port for myocardial dysfunction [1-3]. This group of
patients carry a substantial burden of morbidity and
mortality [4]. Pharmacologic support is commonly lim-
ited to catecholaminesand phosphodiesterase III inhibi-
tors (PDEIs) with levosimendan gaining prominence [5].
There is a lack of suitably powered randomised control
trails to guide the choice of inotrope in this group of
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patients. Both catecholamines and PDEIs are associated
with increased post-operative myocardial oxygen con-
sumption and arrythmogenesis [6]. Additionally catecho-
lamines have also been associated with impaired
coronary vasodilatatory reserve [7].
Levosimendan sensitises myofilaments to calcium by
binding to the calcium saturated troponin C, increasing
their load-independent contraction [8]. The pleiotropic
effects of levosimendan include vasodilatation by open-
ing ATP-sensitive potassium channels (KATP) in vascular
smooth muscle as well as in mitochondrial KATP
channels.
Early clinical trials, though underpowered, have sug-
gested that levosimendan would be useful in the setting
of post coronary revascularisation myocardial dysfunc-
tion. More recently there have been several completed
clinical trials in this group of patients. The principal
objective of this study was to evaluate the association
between levosimendan, compared with conventional
therapy on mortality, in randomised control trialsin
patients having coronary revascularisation.
Materials and methods
Search strategy
The primary search for randomised clinical trials (RCTs)
was conducted using Pubmed, EMBASE and the
Cochrane Registry of Clinical Trials. The search term
used was ‘levosimendan’. The search was combined with
filters to identify RCTs in the Pubmed and EMBASE
database and is available as supplementary material (see
Additional file 1 for details). We also searched the
metaRegister of Controlled Trials using the term ‘levosi-
mendan’ [9]. No language restriction was placed but the
search was limited to adult human subjects. We used
backward snowballing by reviewing the bibliographies of
included RCTs and review articles to identify otherwise
unrecognised publications. The electronic database
search included publications from 1966 and was fina-
lised on 31 August 2010. The study did not require ethi-
cal approval.
Study selection
The authors reviewed all abstracts to identify potential
RCTs in a standardised manner. The inclusion criteria
were reports of RCTs that compared levosimendan to
any other therapy for coronary revascularisation in adult
humans and reported at least one outcome of interest.
Relevant outcomes included mortality, haemodynamic
parameters (for example, cardiac index), cardiac
enzymes, length of stay and post-procedural atrial fibril-
lation. If the abstract suggested that the study could
potentially meet the inclusion criteria, the full text arti-
cle was then retrieved and reviewed. Disagreements
between reviewers were resolved by consensus.
Data abstraction and study characteristics
All included studies were assessed for internal validity
and risk of bias according to the Cochrane Collabora-
tion methods. Each report was assessed for the adequacy
of allocation concealment, blinding, performance of an
intention to treat analysis and the extent of loss to fol-
low-up.
Data included baseline patient characteristics includ-
ing age and co-morbidity, baseline left ventricular ejec-
tion fraction, details of levosimendan dose and specifics
of comparator therapy, type of coronary revascularisa-
tion, haemodynamic and clinical outcome data. When
data was missing attempts were made to contact the
authors.
Data synthesis and analysis
Agreement on inclusion of studies was assessed using
the kappa statistic. Heterogeneity was measured using
the Cochrane Q test and quantified with the I2statistic.
An I2value of > 50% was considered at least moderate
heterogeneity.
Data from individual studies were collected to allow
calculation of odds ratio (OR). The primary analysis
was conducted by means of the Peto fixed effects
method when I2 < 25% and with the random effects
model when I2 > 25%. Weighted mean difference
(WMD) and 95% CI were calculated for continuous
variables (haemodynamics and troponin I). The poten-
tial for bias was assessed by visual inspection of funnel
plots. Sensitivity analyses were conducted by compar-
ing the fixed and random effects models as well as by
evaluating the risk of mortality in studies with a low
risk of bias only. The analysis was performed using sta-
tistical software SPSS 16 (SPSS Chicago, IL, USA) and
Revman 5.0 (available from the Cochrane Collabora-
tion Group). The study was performed in compliance
with the Preferred Reporting Items for Systematic
Reviews and Meta-analysis (PRISMA) statement
[10,11].
Results
There were 680 reports identified by the search, 79 full
text articles retrieved for in depth review. We identified
17 eligible studies involving 729 patients that were
included in the final analysis. Figure 1 describes the flow
and reasons for exclusion. Agreement on study inclusion
was reached in 76 of the 79 cases (kappa = 0.92). The
characteristics of the included studies are described in
Table 1. An appraisal of study quality and risk of bias is
presented in Table 2. Overall studies were of variable
quality and many reports lacked relevant details to
assess selection, performance or reporting bias. A risk of
bias graph is included in the supplementary material
(see Additional file 2 for details).
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Analysis of the data showed that, compared with a
control intervention, levosimendan was associated with
a significant mortality reduction, (19/387 in the levosi-
mendan group vs 39/342 in the control arm) OR 0. 41
(95% CI 0.23 to 0.74, P for overall effect 0.005, P for
heterogeneity = 0.33, I2 = 12% with a total of 729
patients) (Figure 2). A subgroup analysis comparing the





Databases : Pubmed, EMBASE, the 
Cochrane Library and Meta-registry of 
Controlled Clinical trials. (n=680) 
Additional records identified through 
review of references of initially 
retrieved articles (n=0) 
Search results combined n=680 
 601 articles excluded 
-animal studies (n=188) 
-paediatric studies(n=28) 
-reviews (n=150)  
- case reports(n=37) 
-letters(n=70) 
-editorials(n=23) 
-non-RCT clinical trials(n=38) 
-not relevant (n=67) 
Articles screened on the basis of title and 
abstract and 79 full text articles retrieved 
 
62 articles excluded 
-decompensated heart failure=43 
-duplicate publication=2 
-both groups received 
levosimendan=1 
-no relevant outcomes =2 
Included (n=17) 
 
Figure 1 Flow diagram of literature search and selection process of the studies.
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emergency coronary revascularisation was performed.
The elective revascularisation showed a statistically sig-
nificant mortality benefit compared with the emergency
revascularisation group (OR 0.36, 95% CI 0.18 to 0.72, P
for overall effect = 0.003, I2 = 0% compared with OR
0.61, 95% CI 0.19 to 1.89, P for overall effect = 0.39, I2
= 69% respectively). All the emergency revascularisations
were PCI. The overall result was consistent when a ran-
dom effects model was used (OR 0.43 (95% CI 0.21 to
0.89)).
Levosimendan had a favourable effect on cardiac index
(standardised mean difference 1.63, 95% CI 1.43 to 1.83,
P for overall effect < 0.00001) although there was
significant heterogeneity (P < 0.000001 I2 = 95%). A
sub-group analysis was undertaken to explore the het-
erogeneity. Subgroups were defined by the comparator
drug, that is, the placebo, dobutamine or phosphdiester-
ase inhibitors. The sub-group analysis did not show any
difference in treatment effect (Figure 3).
Post revascularisation, troponin I levels were signifi-
cantly higher in the control group compared with the
levosimendan group (mean difference -1.59, 95% CI 1.78
to 1.40, P for overall effect < 0.00001, P for heterogeneity
< 0.00001, I2 = 95%) with 361 patients included (Figure 4).
There was a significantly lower rate of post-revascular-
isation new-onset atrial fibrillation in the levosimendan
Table 1 Description of the studies included in the meta-analysis
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treated group (OR 0.54, 95% CI 0.36 to 0.82, P for effect
= 0.004, P for heterogeneity 0.84, I2 = 0% for 465 patients
(Figure 5). There was also a significant difference in the
length of intensive care stay in favour of levosimendan
compared with control (random effects model, mean dif-
ference - 26.18 hours 95% CI 46.20 to 6.16, P for hetero-
geneity < 0.00001, I2 = 95%, P for overall effect P = 0.01)
(Figure 6). The likelihood of small study bias robustness
was evaluated by inspection of the funnel plot (Figure 7).
Inspection of the funnel plot found no major evidence of
such bias and added to the validity and robustness of the
study. A sensitivity analysis that only included those
studies with a low risk of bias (Table 1) found an OR of
0.25 (95% CI 0.09 to 0.68). A further sensitivity analysis
to establish differential effects based on the comparator
was performed. The largest effect size was observed in
the levosimendan versus phosphodiesterase group (OR
0.23 (95% CI 0.08 to .65)). The levosimendan versus
dobutamine group showed a strong trend in favour of
levosimendan but was not statistically significant (OR
0.54 95% CI 0.25 to 1.17)). The levosimendan versus pla-
cebo group suggested a positive effect in favour of levosi-
mendan but did not achieve statistical significance (OR
0.66 (95% CI 0.11 to 4.08)) (Table 3).
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Figure 2 Forest plot for risk of mortality with subgroups elective and emergency revascularisation.
Figure 3 Forest plot for cardiac index with sub-groups dobutamine, placebo and phosphodiesterase inhibitors.
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Discussion
Cardiogenic shock (CS) is a devastating complication of
ST-segment myocardial infarction (STEMI) and occurs
in 5 to 8% of these patients [12]. Thirty-day survival of
STEMI patients in cardiogenic shock is between 40%
and 60% [12,13]. Despite favourable trends in the last 30
years, survival to 6 years remains poor and may be as
low as 30% [14-16]. This is comparable to many forms
of cancer. Therapeutic options for haemodynamic sup-
port after coronary revascularisation are limited to phar-
macologic or mechanical interventions. Pharmacologic
choices are vasopressors and inotropic drugs. Inotropic
agents are essential to address the contractile dysfunc-
tion that occurs by providing short-term haemodynamic
improvement. However, this happens at a cost of
increased oxygen demand, arrythmogenesis and poten-
tial myocardial injury at a time when the myocardium is
most vulnerable. Data on comparison between inotropes
are scant and recent reports have highlighted the chal-
lenge in selecting the best pharmacologic option
[17-19]. Compared with norepinephrine, the use of
dopamine in patients with cardiogenic shock has been
associated with an increased rate of death [17].
A recent meta-analysis evaluated the use of levosimen-
dan in a variety of patient populations that included
post-cardiac surgery, post-vascular surgery, sepsis,
decompensated heart failure and post percutaneous cor-
onary intervention (PCI) patients [20]. The proposed
mechanisms of myocardial dysfunction in sepsis, after
non-cardiac surgery and in the context of cardiogenic
shock, are all quite disparate [21,22]. This implies that
vasoactive drugs may perform differently, depending on
the prevailing mechanism of shock making the interpre-
tation of a pooled analysis of such a heterogeneous
group of patients difficult. For this reason we limited
this meta-analysis to patients having coronary
revascularisation.
Overall, this study shows a mortality benefit when
levosimendan was used in patients having coronary
revascularisation. The effect was significant in the elec-
tive revascularisation group. The subset of patients
undergoing emergency revascularisation was under-
represented and the mortality benefit in this group was
not statistically significant. This latter analysis is prob-
ably underpowered. Additionally, levosimendan was
associated with favourable outcomes in several clinically
Figure 5 Forest plot comparing rates of post revascularisation atrial fibrillation for levosimendan versus control.
Figure 4 Forest plot of comparison of levosimendan vs control with Troponin I level as the outcome measure outcome.
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important endpoints. The rate of post-revascularisation
atrial fibrillation was reduced. Atrial fibrillation after
coronary revascularisation is associated with a prolonged
hospital stay, increased morbidity and long-term mortal-
ity [23]. The analysis also found levosimendan to be
associated with a reduction in peri-procedural cardiac
troponin I levels. Elevations in cardiac troponin I levels
are a valuable marker of myocardial damage after coron-
ary revascularisation and have been associated with a
significantly higher rate of in-hospital and long-term
mortality [24-27]. The haemodynamic response to levo-
simendan was also favourable. It is likely that the
improvement of haemodynamic profile observed with
levosimendan can be sustained for a longer period of
time compared to dobutamine or milrinone [28]. This is
because levosimendan has a poorly protein-bound active
metabolite and may exert clinical effects for up to a
week [29], at a much lower energy expenditure than
conventional inotropes.
The sub-group analysis comparing levosimendan to
the placebo, dobutamine and phoshodiesterase inhibitors
all showed a favourable trend towards levosimendan
with only the latter group showing statistical signifi-
cance. This observation could be interpreted as potential
harm from exposure to phosphodiesterase inhibitors.
Levosimendan reduced the ICU length of stay by a
mean of 26.18 hours (95% CI 46.20 to 6.16). The esti-
mated mean cost of critical care is US$3,518/day in the
United States and about £1,647/day in the United King-
dom [30,31]. Levosimendan is considerably more expen-
sive than conventional treatment and this probably
warrants further pharmaco-economic evaluation.
The findings of this meta-analysis must be viewed in
the context of other randomised studies and systematic
reviews comparing other vasoactive agents [17,29,32].
Thackray et al. systematically reviewed the use of ino-
tropes in cardiac failure [32]. The drugs included were
beta agonists, dobutamine, dopexamine and phospho-
diesterase inhibitors. Compared with the placebo, these
drugs were found to be associated with a non-significant
trend for increased rate of death (OR 1.5, 95% CI 0.51
to 3.92).
Our study has several limitations. Several studies were
of sub-optimal quality. Eight of the 17 studies included
did not have clear allocation concealment. This has the
potential to exaggerate treatment effects. Only five stu-
dies explicitly stated that the analysis was done by an
intention to treat principle. The study by Fuhrmann had
a small number of events(i.e. all cause mortality at 30
days) and was stopped early for patient benefit [33].
This study may potentially represent an exaggerated
effect size in favour of levosimendan [34]. The sensitivity
analysis considering the effect of levosimendan on mor-
tality across comparator drugs showed a more pro-
nounced effect compared with the phosphodiesterase
group. Comparing levosimendan to placebo is probably
of little value when suitable alternatives exist. These stu-
dies recruited low risk patients with a low event rate.
Lower event rates require larger sample sizes and it is
unsurprising that no statistically significant mortality
difference was demonstrated.
Publication bias may account for some of the effects
observed. Selective reporting of smaller studies, usually
of lower methodological quality will tend to exaggerate
treatment effects. The funnel plot was symmetrical, sug-
gesting a low probability of publication bias. Not all
Figure 7 Funnel Plot for risk of mortality including all studies.
Figure 6 Forest plot comparing length of stay in the levosimendan versus control groups.
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studies reported clinically important outcomes. Only
465 patients were included in the analysis of atrial fibril-
lation rates and only 470 patients were included in the
analysis of length of ICU stay.
Conclusions
This meta-analysis suggests that the use of levosimen-
dan in patients having coronary revascularisation is
associated with a significant reduction in mortality.
Additionally, the use of levosimendan is also associated
with improvement in haemodynamics and reduction in
cardiac biomarkers, length of ICU stay and rate of
atrial fibrillation. A suitably powered RCT is required
to confirm these findings. Additionally, the exact tim-
ing and dosing of levosimendan in patients undergoing
coronary revascularisation needs to be specifically
addressed.
Key messages
• Acute cardiovascular dysfunction after coronary
revascularisation occurs in about 8% to 25% of
patients.
• The short-term use of inotropes is crucial to
restoring haemodynamics and tissue perfusion
though the ideal inotrope in this group of patents is
controversial.
• Levosimendan has a potential role in reducing the
mortality and morbidity associated with coronary
revascularisation.
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